Nuclear protein in testis (NUT)-midline carcinoma (NMC) is a rare, aggressive disease typically presenting with a single t (15;19) translocation that results in the generation of a bromodomain-containing protein 4 (BRD4)-NUT fusion. PER-624 is a cell line generated from an NMC patient with an unusually complex karyotype that gave no initial indication of the involvement of the NUT locus. Analysis of PER-624 next-generation transcriptome sequencing (RNA-Seq) using the algorithm FusionFinder identified a novel transcript in which Exon 15 of BRD4 was fused to Exon 2 of NUT, therefore differing from all published NMC fusion transcripts. The three additional exons contained in the PER-624 fusion encode a series of polyproline repeats, with one predicted to form a helix. In the NMC cell line PER-403, we identified the 'standard' NMC fusion and two novel isoforms. Knockdown by small interfering RNA in either cell line resulted in decreased proliferation, increased cell size and expression of cytokeratins consistent with epithelial differentiation. These data demonstrate that the novel BRD4-NUT fusion in PER-624 encodes a functional protein that is central to the oncogenic mechanism in these cells. Genomic PCR indicated that in both PER-624 and PER-403, the translocation fuses an intron of BRD4 to a region upstream of the NUT coding sequence. Thus, the generation of BRD4-NUT fusion transcripts through post-translocation RNA-splicing appears to be a common feature of these carcinomas that has not previously been appreciated, with the mechanism facilitating the expression of alternative isoforms of the fusion. Finally, ectopic expression of wild-type NUT, a protein normally restricted to the testis, could be demonstrated in PER-403, indicating additional pathways for aberrant cell signaling in NMC. This study contributes to our understanding of the genetic diversity of NMC, an important step towards finding therapeutic targets for a disease that is refractory to current treatments.
INTRODUCTION
Nuclear protein in testis (NUT)-midline carcinomas (NMCs) are rare, lethal tumors typified by the translocation t(15;19)(q14;p13.1). This results in the generation of a gene fusion involving the bromodomain-containing protein 4 (BRD4) and NUT (also referred to as C15orf55) genes. 1 NMCs containing variants of this characteristic gene fusion have also been reported, whereby NUT is fused to another bromodomain containing gene, BRD3, or an unknown partner gene. 2 NMCs generally arise within the midline organs, and while initially described as a pediatric disease, have now been identified in patients ranging from newborn to 78 years of age. 1, 3, 4 Pediatric NMCs were first reported in 1991 in two cases-an 11-year-old female with a poorly differentiated lung carcinoma, 5 and a 22-year-old female with a thymic carcinoma. 6 Cell lines were generated from tumor samples from each of these patients, the first being PER-403 developed by Kees et al., 5 and the second Ty-82 by Kuzume et al. 7 Although only 63 NMC cases have been reported to date, 8 it is likely that many cases have escaped diagnosis. NMCs are difficult to diagnose owing to the lack of characteristic histological features, the fact that it arises in different organs along the midline, and because it occurs in patients across a wide range of ages. 1, 8, 9 NMCs typically possess a straightforward karyotype, involving a single translocation thought to be central to the oncogenic mechanism in these tumors. 1, 10, 11 Although the majority of cases display this simple karyotype, there have been a few instances of NMCs involving karyotypic variations. These include a patient with a t (11;15;19) , 12 and another involving a trisomy 8 in addition to the standard t (15;19) . 13 Furthermore, there have been reports of cryptic BRD4-NUT rearrangements.
14 In this report we characterize an unusual NMC cell line, PER-624, with a complex karyotype and a cryptic translocation of BRD4 and NUT. This we compare with the 'standard' NMC cell line, PER-403. 5 Using RNA-Seq we report a novel breakpoint for the fusion of these genes and the expression of multiple isoforms of this fusion. This study increases our understanding of the genetic complexity of NMC, an important step in the search for more effective therapies for this aggressive disease.
RESULTS

Clinical presentation
A 16-year-old girl presented at Princess Margaret Hospital for Children, Perth, Australia, with a 2-week history of cough, fever and right-sided chest pain. Radiological investigations revealed a large right-sided posterior mediastinal mass with secondary right middle and lower lobe lung collapse/consolidation. There was no evidence of metastatic disease. Definitive diagnosis was poorly differentiated lung carcinoma (suspected NMC), and analysis of the tumor tissue demonstrated the karyotype 46, XX, t(1;18;7)(q42;q11.2;q21), t(6;19)(q13;p13.1), t(3;13)(q25;q14) and t(12;15)(q13;q22). The t(6;19) translocation was thought to be a possible variant of the t(15;19) translocation typical of NMC cases. The patient commenced therapy with combination intravenous docetaxel, cisplatin and 5-fluorouracil, which was poorly tolerated owing to the development of 5-fluorouracil-induced cardiotoxicity, requiring significant inotrope support for severe left ventricular dysfunction. Radiological re-evaluation on recovery from this cycle of chemotherapy demonstrated disease progression. Therapy was changed to a combination of intravenous ifosfamide and doxorubicin with dexrazoxane as a cardioprotectant. Her disease demonstrated clinical and radiological response, and this chemotherapy combination continued to a total of five cycles. Therapeutic radiotherapy to consolidate response commenced, but the patient developed massive recurrence that proved resistant to further ifosfamide and doxorubicin chemotherapy. The patient died of rapidly progressive, resistant disease 10 months after presentation.
Fluorescence in situ hybridization mapping reveals a cryptic BRD4-NUT translocation in the NMC cell line, PER-624 The PER-624 cell line was established from a tumor biopsy sample obtained from the above patient, using previously described methodology. 5 In keeping with the primary tumor specimen, karyotypic analysis of this line confirmed the multiple translocations and absence of the standard NMC t (15;19) . We therefore employed fluorescence in situ hybridization (FISH) to map the chromosome 6 and 19 breakpoint regions. Mapping of sequential BAC clones identified two breakpoints on chromosome 19 (Supplementary Figure 1A) . This confirmed a reciprocal translocation of the short arm of chromosome 19 onto the long arm of chromosome 6 (Figure 1a ), and identified a large deletion of chromosome 6q14-15 (indicated by an asterisk in Figure 1a ). FISH also indicated that a region of 19p13.1 of B1.5 Mb, containing BRD4, was cryptically inserted into chromosome 15, upstream of the position of the NUT gene (Figure 1a ). This colocalization was confirmed using PCR-generated FISH probes designed to the BRD4 gene, and a BAC containing NUT (Figure 1b) . Supplementary Figure 1B illustrates the inversion that occurs prior to insertion, bringing the BRD4 and NUT genes into close proximity. The identification of a cryptic insertion of the BRD4 region of chromosome 19 into chromosome 15 implicated NUT involvement, despite the lack of evidence for this at the karyotypic level.
Previous descriptions of BRD4-NUT fusions have applied inconsistent exon nomenclature in the literature. As such we have provided a new annotation based upon the current isoforms present in Ensembl Version 68. Historically, two isoforms of BRD4 have been documented and are referred to as the 'long isoform' and the 'short isoform' (Figure 1c) . The former involves all exons except Exon 12 (herein labeled 12b), whereas the latter terminates at Exon 12b. Isoform 3 (BRD4-202) is a recent addition to Ensembl that provides evidence for a new Exon 1a B52 kb upstream from Exon 1b, and the novel Exon 12a. Three NUT isoforms exist as shown in Figure 1d . Isoform 1 represents the standard NUT isoform previously described in NMC publications. Isoforms 2 and 3 describe novel exons upstream of (and partially overlapping with) the standard Exon 1 (now Exon 1b). All t(15;19) BRD4-NUT fusion sequences published to date, either at the transcript level 2, 9, [15] [16] [17] [18] [19] or at the genomic level, 19 invariably represent fusion of Exon 11 of BRD4 to Exon 2 of NUT, according to the annotation provided in Figure 1 . This we refer to herein as the 'standard' BRD4-NUT breakpoint in NMC.
RNA-Seq reveals a novel BRD4-NUT fusion transcript isoform Based on the apparent proximity of BRD4 and NUT in PER-624 indicated by FISH, we employed Southern blotting to detect the BRD4-NUT breakpoint. A locus-specific BRD4 probe and restriction enzymes were selected based on their position relative to the BRD4-genomic breakpoint location in 'standard' cases. [17] [18] [19] These experiments (not shown) indicated that if a BRD4-NUT fusion existed in PER-624, it must represent a non-standard NMC breakpoint. With this in mind, next-generation transcriptome sequencing (RNA-Seq) was performed to investigate which, if any, fusions between BRD4 and NUT might be expressed in the PER-624 line. The PER-403 cell line 5 has previously been identified as having a 'standard' BRD4-NUT fusion gene and was used for comparison. From PER-624 we obtained 50 181 160 Â 75 bp sequencing reads, and from PER-403 98 117 732 Â 100 bp reads, comprising 3.76 and 9.81 Gb of data, respectively. We have recently described a novel program, FusionFinder, to detect expressed fusion transcripts in RNA-Seq data, 20 and used this approach to examine the RNA-Seq data from the NMC cell lines. As expected, sequences representing the standard BRD4-NUT fusion transcript (that is reads spanning from BRD4 Exon 11 to NUT Exon 2) were identified in the PER-403 data (Table 1 ). In PER-624, however, we identified the expression of a novel BRD4-NUT fusion transcript, involving Exon 15 of BRD4 fused to Exon 2 of NUT (Table 1 ). An alignment of reads evidencing this novel fusion transcript is shown in Supplementary Figure 2 . Although this fusion transcript differs from the standard NMC fusion sequence, it does retain an open-reading frame across the fused exons. Only one isoform of the BRD4-NUT fusion gene was identified in PER-624, however, two isoforms were identified in PER-403, namely the 'standard' fusion and an additional out-of-frame fusion that fused BRD4 Exon 11 to NUT Exon 1b (Table 1 ). There was no evidence of expression from any reciprocal fusion.
We assessed the expression of BRD4 and NUT in each cell line by calculating the relative representation of each exon within the RNA-Seq data ( Figure 2 ). The BRD4 breakpoints in the two cell lines can clearly be seen from this analysis, with a substantial drop in expression after Exon 11 in PER-403 and after Exon 15 in PER-624 ( Figure 2 ). The relative abundance of each of the different isoforms can be calculated by comparing the signals arising from specific exons or groups of exons (Table 1) . Although the primary fusion transcripts were expressed at similar levels in PER-624 and PER-403 (normalized read frequencies of 164 and 157, respectively), the out-of-frame fusion in PER-403 was only present at minimal levels ( Table 1) . Both long and short isoforms of wild-type BRD4 were expressed in the cell lines, but at much lower levels (read frequency o60) than the main BRD4-NUT fusion transcripts. Thus, the fusion transcripts in NMC appear to be significantly overexpressed compared with wild-type BRD4 transcripts. To map the full-length sequence of the fusion genes in the two cell lines, we further analyzed the RNA-Seq data for alternative splicing of canonical exon boundaries of BRD4 and NUT (Supplementary Table 1 ). In PER-403 a splice variant joining Exon 2 with Exon 8 of BRD4 was identified at low frequency (four reads). No alternative splicing was evident in PER-624. Standard exon usage was also seen for NUT in both cell lines, including sequences that spanned the Exon 1b/Exon 2 boundary (eleven reads in PER-403 and eight reads in PER-624) (Supplementary Table 1 ). This suggests expression either of wild-type NUT, or alternative fusion isoforms containing this exon (as seen in PER-403). Abbreviations: BRD4, bromodomain-containing protein 4; NMC, NUT midline carcinoma; NUT, nuclear protein in testis. a Exons used for assessing abundance were those specific to wild-type BRD4 transcripts and not shared by fusion transcripts expressed from the respective cell line.
b Read frequencies (Freq) were normalized for the total number of RNA-Seq reads obtained for each cell line.
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A schematic of the novel BRD4-NUT fusion identified from PER-624 and the three possible isoforms for PER-403 are shown in Figure 3a . The bromodomains and extra-terminal domains of BRD4 are intact in all but the last isoform of PER-403. The additional three exons present in the PER-624 isoform encode a series of polyproline repeats, one of which is predicted to form a potential helix structure.
Confirmation of fusion transcript expression
We amplified the BRD4-NUT fusion transcript in PER-403 by reverse transcription (RT)-PCR ( Figure 3b ) using primers designed by Engleson et al. 18 and confirmed the product by sequencing. For PER-624, we amplified the breakpoint using a forward primer designed to Exon 15 of BRD4 and the same NUT reverse Exon 2 primer as above (Figure 3b) , with sequencing confirming the novel breakpoint. The expression of Exon 1b of NUT, indicating potential expression of wild-type NUT in these cells was also assessed. Primers designed in Exon 1b and Exon 2 of NUT-amplified products in both cell lines (Figure 3b ), validated by Sanger sequencing. Next we assessed expression of BRD4-NUT fusion protein by immunoblot, using nuclear protein from rat testis as a control for wild-type NUT (Figure 3c ). Two bands were evident in PER-403, the first corresponding to the 'standard' BRD4-NUT fusion protein, which is known to run B50 kDa higher than its theoretical size of 200 kDa. 14 The second band corresponds to the Exon 2-8 spliced fusion isoform identified from the RNA-Seq data, also running at B50 kDa higher than predicted. Evidence of a weak band corresponding to wild-type NUT was also seen in the PER-403 protein lysate but not in PER-624. A B280 kDa band corresponding to the larger theoretical protein size of the novel fusion isoform was detected in the PER-624 protein lysate (Figure 3c ), confirming the translation of this transcript.
Nested PCR identifies BRD4-and NUT-genomic breakpoints Nested primers were designed to BRD4 Exon 15 or Exon 11 (for PER-624 and PER-403 respectively), and to Exon 2 of NUT. Amplification from genomic DNA yielded a product of B8.6 kb from PER-624 and 5.4 kb from PER-403. Examination of the sequence for PER-624 revealed a fusion of Intron 15 of BRD4 to B3.6 kb upstream of Exon 1b of NUT (Figure 3d ). The direction of the chromosome 19 fragment indicates that it was inverted before insertion into chromosome 15q14, resulting in the 5 0 -3 0 directionality of BRD4-inserted upstream of NUT (Supplementary Figure 1) . The genomic breakpoint in PER-403 fused Intron 12a to B1.5 kb Table 1 .
Novel (Figure 3e ). This indicated that in both cell lines the BRD4 breakpoint is intronic, and the NUT breakpoint is upstream of Exon 1b, that is, upstream of the start of the openreading frame for the primary NUT transcript.
Knockdown of BRD4-NUT promotes a differentiated phenotype in PER-624 To assess the function of the fusions, we transfected both cell lines with small interfering RNA (siRNA)s targeting NUT, as all expressed 15 16 1b Figure 3 . Validation of BRD4-NUT breakpoints and fusion isoforms in PER-624 and PER-403. (a) Schematic representation of the identified NMC fusion isoforms. PER-624 expresses a novel fusion isoform, which retains Exons 13-15 of BRD4 that code for a series of polyproline repeats (PP). PER-403 expresses the 'standard' NMC fusion isoform, an out-of-frame fusion isoform, including Exon 1b of NUT, and the in-frame spliced fusion isoform in which Exons 3-7 of BRD4 are missing. The location of the two bromodomains (BD), the extra-terminal domain (ET) and the PP in BRD4 are shown; (b) RT-PCR validation of the BRD4-NUT fusion breakpoints in PER-403 and PER-624 and the detection of a product spanning the NUT Exon 1b/ Exon 2 boundary. Saos2 (an osteogenic sarcoma cell line) was used as a negative control, as the BRD4-NUT fusion gene is not present in this cell line. GAPDH was used as a positive control; (c) Immunoblot with the NUT rabbit monoclonal antibody (Cell Signaling Technology) on nuclear protein lysates from PER-403, PER-624 and rat testis. A strong band of B140 kDa was seen in the rat testis protein extract, corresponding to wild-type NUT. Two bands were evident in PER-403, the top band was B250 kDa (corresponding to the standard BRD4-NUT fusion protein). The second band was B40 kDa smaller and is consistent with the smaller fusion isoform missing BRD4 Exons 3-7 that was identified from the RNA-Seq analysis. A band corresponding to wild-type NUT is present in PER-403 but not PER-624 (note that a non-specific band, just larger than that of wild-type NUT is evident in all three lanes). A band of B280 kDa was detected for PER-624, corresponding to the anticipated protein size of the PER-624 fusion isoform; (d) Schematic of the genomic breakpoints in PER-624, being B30 bp upstream of the end of Intron 15 of BRD4 and B3.6 kb upstream of Exon 1b of NUT; (e) Schematic of the genomic breakpoints in PER-403, being B1.7 kb downstream of BRD4 Exon 11 (within Intron 12a) and B1.5 kb upstream of Exon 1b of NUT.
Novel fusion isoforms in NUT midline carcinoma K Thompson-Wicking et al fusions contain the full coding sequence of this gene. Knockdown was assessed after 24 h by quantitative RT-PCR, using primers designed to detect NUT-containing transcripts (that is, both wildtype NUT and fusion isoforms), and was associated with a B50% decrease in mRNA expression in both cell lines (Figure 4a ). Protein was extracted at this same time point and analyzed by immunoblot. Figure 4c demonstrates that the high-molecular weight band in PER-624 is similarly reduced by B50% in response to NUT siRNA (both at 50 and 100 nM, lanes 4 and 8) compared with the scrambled siRNA control or mock-treated cells, verifying that this band represents expression of the novel BRD4-NUT fusion protein. The reduction in expression of this protein in response to 50 nM NUT siRNA in independent experiments is quantified in Figure 4b . Notably, there are up to three additional bands (170-220 kDa) visible in the control lanes from PER-624, which also respond to NUT siRNA treatment ( Figure 4c ). As no evidence was found at the transcriptome level for additional isoforms of BRD4-NUT in this cell line, this may represent either degradation products of the primary fusion or alternatively spliced isoforms that are transcribed at levels below the level of detection of RNA-Seq. In PER-403, NUT siRNA resulted in even greater reduction of the primary BRD4-NUT fusion (Figures 4b and d) , and also reduced the secondary band at B215 kDa, which is consistent with the smaller BRD4-NUT fusion lacking Exons 3-7 of BRD4. A third prominent band visible in untreated cells, as for PER-624, may reflect degradation products or low-level alternate isoforms that escaped detection by RNA-Seq. A product corresponding to wild-type NUT, which also responds to knockdown by siRNA, is clearly visible in PER-403 (Figure 4d ), but not PER-624 (Figure 4c ). The functional consequences of fusion knockdown on the NMC cell lines were assessed 96 h after siRNA transfection by immunohistochemistry (IHC). Figure 5 (top left panel) shows that in PER-624 control cells (scrambled siRNA), most cell nuclei were positive for NUT protein, with a distinctly punctate pattern of staining. In contrast, treatment with NUT siRNA significantly reduced the number of cells expressing NUT ( Figure 5 , (top right) and Figure 6d ). Knockdown was associated with both increased staining intensity for cytokeratin and an increase in cell size ( Figures 5, 6a and b) , as well as a decrease in proliferation as assessed by Ki67 staining (Figures 5 and 6c) , consistent with epithelial differentiation. Dual staining for NUT and cytokeratin ( Figure 5, bottom) showed that cells positive for NUT expressed limited cytokeratin, and that the cellular loss of NUT expression following knockdown was accompanied by an increase in cell size and cytokeratin staining. These phenotypic changes paralleled those seen following siRNA knockdown of the fusion protein in PER-403 (Figure 7) , which have previously been described, 2, 11 and demonstrated that the novel BRD4-NUT fusion expressed in PER-624 is functional and responsible for maintaining the undifferentiated and proliferative phenotype of these cells.
DISCUSSION
The BRD4-NUT fusion generated by t(15;19) translocation is thought to be the primary oncogenic driver in NMC and blocks cellular differentiation, 1,2 potentially by sequestering histone acetyltransferases. 10, 21 As NMCs are refractory to current therapies, with median survival o7 months 8 and only one survivor reported to date, 22 there is an urgent need to find novel strategies to improve patient outcome. This has led to recent studies, demonstrating the potential use of histone deacetylase inhibitors 11 and the bromodomain and extra-terminal domain (BET) inhibitor JQ1. 23 The BET inhibitors target the wider BRD Novel fusion isoforms in NUT midline carcinoma K Thompson-Wicking et al family of proteins and have shown efficacy in a variety of cancers, [24] [25] [26] apparently through the modulation of MYC. 26, 27 This indicates that besides its direct involvement in NMC via gene translocation, BRD4 may have a more general role in oncogenic pathways. 28, 29 In this study, we have characterized a novel BRD4-NUT breakpoint in PER-624, an NMC cell line that also exhibited multiple other translocations, in contrast to the majority of NMC patients described to date. We further identified a deletion of the region 6q14.3 to 6q15 that borders one of the translocated regions, resulting in the loss of heterozygosity of this locus. Although the genes therein have not to date been implicated in any other cancers or diseases, their single copy state may have a role in the development of this carcinoma. Together, these features contribute additional complexity to the genomic aberrations associated with this disease. In both PER-403 and PER-624, the BRD4 breakpoint is intronic but the NUT breakpoint is upstream of the NUT transcription start site in Exon 1b. The only other published genomic analysis of NMC found the BRD4 breakpoint to be located in Intron 11, and the chromosome 15 breakpoint to be B610 bp upstream of NUT Exon 1b. 19 The out-offrame NMC mRNA fusion of BRD4 Exon 11 to NUT Exon 1 identified by Engleson et al. 18 suggests a similar breakpoint structure. With the addition of the two genomic breakpoints reported in the Novel fusion isoforms in NUT midline carcinoma K Thompson-Wicking et al present study, it is evident that all four NMCs contain a breakpoint upstream of the standard Exon 1b of NUT. This demonstrates that generation of the mature fusion transcript from the translocated region involves RNA-splicing to remove this exon, and may be a common mechanism in NMCs. Given the consistent positions of the NUT breakpoint, it raises the possibility that this region is genomically unstable, or that the t(15;19) translocations may occur because of the presence of repetitive elements or microhomologies between this region and the BRD4 gene region. The novel fusion protein identified in PER-624 is larger than the 'standard' protein, reflecting the additional Exons 13-15 of BRD4. Transient knockdown of the fusion in this cell line promoted features of epithelial differentiation, demonstrating that the protein is functional, and that its expression underpins the neoplastic phenotype of PER-624. In PER-403, we also identified for the first time the expression of multiple isoforms of the 'standard' BRD4-NUT fusion. The omission of BRD4 Exons 3-7 in the smaller isoform, and therefore the bromodomains, makes it unlikely that this protein could function in the same way as the 'standard' fusion protein, so the exact functional role of this variant remains to be determined. Finally, we have demonstrated expression of wild-type NUT in an NMC line, a protein that is normally restricted to the testis. Although the mechanism for this is not yet clear, altered microRNA regulation or transcription factor signaling in these cells are possible explanations. Little is known about the function of wild-type NUT, but off-target expression of a testis-specific factor could potentially contribute to the aggressive nature of these carcinomas. Collectively these observations reveal greater diversity than previously suspected in the genetic aberrations driving NMC. Understanding this diversity and identifying the critical oncogenic mechanisms is central to developing optimal therapeutic interventions for this aggressive disease.
MATERIALS AND METHODS
Cell culture
The PER-403 and PER-624 cell lines were grown in RPMI-1640 supplemented with 2 mM L-glutamine, 10 nM 2-mercaptoethanol, 10% fetal calf, non-essential amino acids and pyruvate.
Fluorescence in situ hybridization
FISH studies were performed using BAC probes labeled with Spectrum Orange or Spectrum Green (Vysis, Downers Grove, IL, USA). All BACs were checked for chromosomal location on normal peripheral blood chromosomes before use, and were hybridized at a final concentration of 15 ng/l. To investigate colocalization of BRD4 and NUT, a BAC containing NUT (RP11-122P18) was hybridized with probes amplified from the BRD4 gene using LongAmp Taq DNA Polymerase (New England BioLabs Inc., Ipswich, MA, USA).
RNA-Seq and fusion identification
Total RNA was isolated (TRIzol; Invitrogen, Mulgrave, VIC, Australia) from PER-624 and PER-403, and purified using the RNeasy mini kit (Qiagen, Valencia, CA, USA) according to the manufacturer's instructions. RNA-Seq was conducted at the Australian Genome Research Facility (Brisbane) using the Illumina Genome Analyzer II. To identify fusion genes, we used our previously developed software FusionFinder. 20 Briefly, this pipeline aligns all sequence reads against a normal transcriptome and identifies those that align to two different genes, filtering false positives arising from paralogues or repeat gene regions. To assess the relative abundance of BRD4 and NUT transcripts the genomic sequence of both genes was exported from Ensembl. RepeatMasker was used to mask repeat regions within this sequence after which RNA-Seq reads were aligned using TopHat. 30 The frequency with which each nucleotide was represented in aligned reads was calculated and normalized to total read count for each cell line to assess the comparative levels of expression of each BRD4 and NUT exon.
RT-PCR and sequencing
Total RNA was reverse transcribed using gene specific priming and Omniscript RT (Qiagen). Primers for PCR and sequencing of fusions were BRD4Exon15Fwd (3 0 -TTCCACCCACATCCAACAGC-5 0 ) and BRD4Exon11Fwd (3 0 -AAGTTGATGTGATTGCCGGCTCCTC-5 0 ). The same reverse primer was used for both cell lines, NUTExon2Rev (3 0 -CTGAAGGCATGATGGGCTGTGG-5 0 ). The expression of Exon 1b of NUT was verified using primers in Exon 1b (NUTExon1bFwd-3 0 -TTCCAGACAGCCACAGTTAG-5 0 ) and NUTExon2Rev. Saos2 (an osteogenic sarcoma cell line) was used as a negative control for fusion expression. Products were amplified using GoTaq Flexi DNA polymerase (Promega, Madison, WI, USA).
Genomic breakpoint sequencing
The PER-624 genomic breakpoint was amplified by nested PCR using LongAmp DNA polymerase (NEB). Primary amplification was performed ) were transfected with 100 nM siRNA in 100 ml Lonza solution R using program T-027 of the Amaxa Nucleofector II (Lonza, Gaithersburg, MD, USA). PER-624 and PER-403 cells were harvested 24 h post transfection for mRNA and protein analysis, and 96 h post transfection for IHC.
Quantitative RT-PCR Quantitative RT-PCR was carried out in an ABI PRISM 7000 Sequence Detection System (Applied Biosystem, Mulgrave, VIC, Australia). As it was not possible to design primers that could distinguish wild-type NUT from fusion transcripts (NUT Exon 1b being retained in the fusion gene), primers designed to NUT Exon 7 were used to amplify all transcripts containing NUT sequence. These primers were NUT_2931_FOR (5 0 -GGGAACCAG GAATGCCATA-3 0 ) and NUT_3135_Rev (5 0 -GCTCTCTGGCTGCCCTGA-3 0 ). The housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was amplified using GAPDH_Fwd (5 0 -CTTCGCTCTCTGCTCCTCCT-3 0 ), GAPDH_Rev (5 0 -GGGCCATCCACAGTCTTCTG-3 0 ). PCR reactions were performed in triplicate using complementary DNA synthesized as for RT-PCR and Power SYBR Green PCR Master Mix (Applied Biosystem) as recommended by the manufacturer. Data were analyzed by comparative Ct Method, normalizing to GAPDH.
Immunoblot
Nuclear protein was extracted from PER-403, PER-624 or rat testis using a hypotonic buffer (20 mM HEPES, pH 7.9; 0.4M NaCl, 0.1 mM EDTA, 0.1 mM EGTA and 1.0 mM DTT), containing protease inhibitors aprotinin and leupeptin. Protein lysates were quantified using the Invitrogen Qubit 2.0 Fluorometer protein assay. Denatured nuclear protein (20 mg) was separated using an Invitrogen NuPage Novex Tris-Acetate 3-10% gel and transferred to a GE Healthcare Amersham Hybond-ECL membrane (GE Healthcare, Piscataway, NJ, USA). The blots were probed with a NUT rabbit monoclonal antibody (Cell Signaling Technology; Boston, MA, USA) and Actin pan Ab-5 mouse monoclonal antibody as loading control (Thermo Scientific, Scoresby, VIC, Australia). The secondary antibodies were antirabbit IgG HRP-linked antibody (Cell Signaling Technology) and ECL antimouse IgG, peroxidase-linked species specific F(ab 0 )2 fragment (from sheep) (GE Healthcare). The bands were visualized using an Amersham ECL western blotting detection reagents (GE Healthcare) and quantified by densitometry, normalizing to B-actin.
Immunohistochemistry
Ninety-six hours after transfection of siRNA, cell blocks were fixed and sectioned. Following rehydration and heat-mediated antigen retrieval, non-specific endogenous peroxidase staining was blocked with 3% hydrogen peroxide. For single staining, primary antibody (anti-NUT, C52B1, Cell Signaling Technology; anti-cytokeratin, AE1/3, Dako, Carpinteria, CA, USA; or anti-Ki67, MIB-1, Dako) was applied for 60 min at room temperature, the secondary antibody (Dako EnVision þ Dual Link-HRP) applied neat for 30 min, and the reaction visualized with Dako Liquid DAB þ Substrate-Chromogen System. For dual IHC, the protocol for NUT was initially followed before adding the AE1/3 antibody after DAB rinsing and blocking with serum-free protein. A rabbit anti-mouse link immunoglobulin (Dako, Glostrup, Denmark) was applied followed by mouse anti-APAAP complex (AbD Serotec, Oxford, UK). This was visualized with Liquid Permanent Red (Dako). Slides were counterstained with Carazzi's haematoxylin. ImageJ64 (http:/rsbweb.nih.gov/ij/) was used to quantify IHC.
